Efficient synthesis and evaluation of bimodal ligand NETA

The efficient and short synthetic route to the structurally novel bimodal ligand NETA for antibody-targeted radiation therapy (radioimmunotherapy, RIT) of cancer was developed. The structure of NETA was determined by X-ray crystallography. The arsenazo-based UV spectroscopic complexation kinetics data suggest that NETA is a promising chelator for use in RIT applications of 212Bi, 213Bi, and 177Lu.

Figure optionsDownload as PowerPoint slide